

# Capital Park

## 2Q20 results review

Capital Park reported its 2Q20 results below our expectations with operating loss of PLN 76.5m (vs. our est. loss PLN 19.3m) driven by negative revaluations of PLN 83m. Below please find key highlights:

- **Revenues** amounted to PLN 14.3m (flat q/q, 19% above our expectations.). As a reminder, a decline of 55% y/y is related to the disposal of shares in Dakota Investment (Eurocentrum Office Complex) in Nov-2019. The company pointed that due to Anti-crisis Shield (temporary discounts for tenants) rental income was lower by 39%.
- **NOI** came in at PLN 10.5m (35% above our expectations), implying NOI margin of 73.5% (comparable y/y).
- **Operating loss** amounted to PLN 76.5m (vs. operating profit of PLN 86.9m in 2Q19 and our forecast loss PLN 19.3m). The result was negatively affected by revaluation loss of PLN 83.0m related to EUR/PLN FX rate and negative impact of COVID-19 outbreak of valuation of properties. The value of retail projects (Royal Wilanów, Galeria Zaspá, Vis-à-vis Łódź) declined given higher yields.
- **Net loss** came in at PLN 61.3m (vs. our est. PLN -9.2m). Net financial income amounted to PLN 5m (vs. our est. PLN 10m) and net results was positively affected by income tax of PLN 10m.
- Operating cash flow amounted to PLN 4.3m, while investing cash flow amounted to PLN 58m (the company estimates remaining capex on Fabryka Norblina of PLN 534m). As of end-2Q20 the company had net debt of PLN 568m (incl. IFRS16). NAV amounted to PLN 9.08 per share as of end-2Q20. As a reminder the company has assets held for sales with NAV of PLN 271m.

*Opinion: Negative, as reported results were below our expectations. However we note that around PLN 30m revaluation was related to non-cash FX change, as the company reported that the value of completed projects declined by 2% in comparison to end-4Q19 (from EUR 148m to EUR 146m), while value of projects under construction increased by 7% at the same time (mainly due to capex on Fabryka Norblina project). The company stated that Fabryka Norblina project is developed in line with the schedule (completion planned in 2Q21), while remaining capex on this project amounts to PLN 568m; the project is pre-let in 64%. Capital Park currently trades with nearly 27% discount to its NAV.*

Figure 1. Capital Park quarterly results (PLNm)

PLNm	2Q19	3Q19	4Q19	1Q20	2Q20	y/y	2Q20E	vs. Ipopema
Revenues	31.7	31.9	27.8	14.4	14.3	-55%	12.0	19%
Costs related to inv.prop.	-8.0	-8.0	-7.4	-4.4	-3.8	-53%	-3.5	8%
<b>Net operating profit</b>	<b>23.7</b>	<b>23.9</b>	<b>20.4</b>	<b>10.0</b>	<b>10.5</b>	<b>-55%</b>	<b>7.8</b>	<b>35%</b>
G&A costs	-6.7	-5.6	-3.3	-3.2	-3.4	-49%	-3.2	7%
Revaluation of inv.prop.	69.4	61.9	27.5	91.6	-83.0	n.m.	-24.3	n.m.
Gain on disposal	0.0	0.0	130.5	0.0	0.0	n.m.	0.0	n.m.
<b>EBIT</b>	<b>86.9</b>	<b>82.7</b>	<b>169.0</b>	<b>98.0</b>	<b>-76.5</b>	<b>n.m.</b>	<b>-19.3</b>	<b>n.m.</b>
<b>EBIT adj.</b>	<b>17.5</b>	<b>20.7</b>	<b>11.0</b>	<b>6.5</b>	<b>6.6</b>	<b>-62%</b>	<b>5.0</b>	<b>31%</b>
Net financial costs	-4.2	-62.4	35.7	-53.1	5.2	n.m.	10.1	n.m.
Pre-tax profit	82.7	20.2	204.7	44.9	-71.2	n.m.	-9.2	n.m.
Income tax	-17.8	-10.8	-31.8	-13.6	9.9	n.m.	0.0	n.m.
<b>Net profit</b>	<b>64.9</b>	<b>9.4</b>	<b>172.9</b>	<b>31.3</b>	<b>-61.3</b>	<b>n.m.</b>	<b>-9.2</b>	<b>n.m.</b>
NOI margin (%)	74.7%	75.0%	73.5%	69.4%	73.5%	-	65.0%	-
Net debt	1,093	1,180	-91	290	568	-	-	-

Source: Company, IPOPEMA Research, \*excluding revaluations and gain on disposals

Real Estate

## Capital Park

BUY

FV PLN 8.25

24% upside

Price as of 3 September 2020 PLN 6.66

### Analyst

Marek Szymański  
marek.szymanski@ipopema.pl  
+ 48 22 236 94 12

This document has been prepared by IPOPEMA Securities S.A. with its registered seat in Warsaw, Prózna 9, 00-107 Warsaw, Poland, entered into the Register of Entrepreneurs of the National Court Register maintained by the District Court for the City of Warsaw, XII Commercial Division of the National Court Register under entry number KRS 0000230737, the initial capital and paid capital in the amount of PLN 2.993.783,60, NIP 5272468122, [www.ipopema.pl](http://www.ipopema.pl). IPOPEMA Securities S.A. is supervised by the Polish Financial Supervision Authority (Komisja Nadzoru Finansowego), Piękna 20, 00-549 Warsaw, Poland.

This document has been prepared by IPOPEMA Securities S.A. as a part of the Warsaw Stock Exchange Research Coverage Support Program ("Program") and was commissioned by the Warsaw Stock Exchange SA ("WSE"). Information about the Program is available at <https://www.gpw.pl/gpwpa>. The copyright to the document is vested in the WSE. For preparation of the document, IPOPEMA Securities S.A. will be remunerated by the WSE on the terms specified in the agreement concluded between IPOPEMA Securities S.A. and the WSE.

This document was prepared by IPOPEMA Securities S.A. for information purposes only. This document is addressed to IPOPEMA Securities S.A. clients entitled to receive it on the basis of contracts for the provision of services. This document, using media distribution channels, may also reach other investors. It has been produced independently of the company mentioned in this document and any forecasts, opinions and expectations are entirely those of IPOPEMA Securities S.A. Unless otherwise specified, the estimates and opinions contained in the document constitute an independent assessment of IPOPEMA Securities S.A. analysts preparing the document as of the date of issuing the document.

IPOPEMA Securities S.A. prepared this document with the preservation of all adequate diligence, thoroughness and reliability on the basis of publicly available information which IPOPEMA Securities S.A. believes to be reliable. The sources of data are primarily: Bloomberg, Reuters, EPFR, Polska Agencja Prasowa, WSE, Główny Urząd Statystyczny, Narodowy Bank Polski, financial press, online financial and economic services. While due diligence has been taken by IPOPEMA Securities S.A. to ensure that the facts stated herein are accurate and that any forecasts, opinions and expectations contained herein are fair and reasonable, IPOPEMA Securities S.A. has not independently verified all the information given in this document. Accordingly, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this document. The opinions expressed in the document can change without notice and IPOPEMA Securities S.A. is under no obligation to keep these opinions current. None of the IPOPEMA Securities S.A. or any other person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith. This document nor any copy hereof is not to be distributed directly or indirectly in the United States, Australia, Canada or Japan.

This document does not constitute any offer to sell or induce any offer to buy or sell any financial instruments, can not be relied on in connection with any contract or liability and does not constitute advertising or promotion of a financial instrument or the company. Investment decisions should only be made on the basis of a prospectus or other publicly available information and materials.

The document was prepared without taking into account the needs and situation of the recipients of the document. When preparing the document, IPOPEMA Securities S.A. does not examine the recipient's investment objectives, risk tolerance level, time horizon and financial standing of the investors. The company or the financial instruments discussed in the document may not be suitable for the users of the document, i.e. it may not be suitable for the specific objectives and time horizon or the financial situation. Information included in the document can not be regarded as a substitute for obtaining investment advice service. The value of financial instruments may fluctuate, including declines. Changes in FX rates may have an adverse effect on the value of investments. The investment in financial instruments is linked to investment risks including loss of entire or part of the invested capital. Past performance is not necessarily indicative of future results. IPOPEMA Securities S.A. points out that the price of financial instruments is affected by many different factors that are or may be independent of the company and the results of its operations. These include, among others changing economic, legal, political and tax conditions. IPOPEMA Securities S.A. may have issued in the past or may issue other documents in the future, presenting other conclusions, not consistent with those presented herein document. Such documents reflect different assumptions, points of view and analytical methods adopted by the analysts preparing them.

Investors should be aware that IPOPEMA Securities S.A. or its related entities may have a conflict of interest that could affect this document's objectivity. The investor should assume that IPOPEMA Securities S.A. or its related entities may provide services in favour of the company and obtain remuneration on this account. They may also have another financial interest with respect to the company. IPOPEMA Securities S.A. or its related entities may seek to do business with the company or other entities mentioned in this document. IPOPEMA Securities S.A. has an organizational structure and internal regulations in place to ensure that the client's interests are not compromised in the event of a conflict of interests, in relation to preparing this document. This document was prepared irrespective and independently of the interests of IPOPEMA Securities S.A., the company that is the subject of this document and holder of financial instrument issued by aforementioned company. IPOPEMA Securities S.A., its shareholders, employees and associates may hold long or short positions in the company's financial instruments or other financial instruments related to the company's financial instruments.

On the order of the Warsaw Stock Exchange S.A. ("WSE"), IPOPEMA Securities S.A. creates analytical materials for the following companies: AC S.A., Capital Park S.A., Mirbud S.A., PKB Pekabex S.A., Vigo System S.A. The WSE has proprietary copyrights to these materials. For the preparation of IPOPEMA Securities S.A. receives remuneration from the WSE. Information on the program is available on the website <https://www.gpw.pl/gpwpa>.

IPOPEMA Securities S.A. uses a number of valuation methodologies including discounted cash flows models (such as discounted operating earnings or dividend discount model), and earnings and cash-flow based models, which are often related to comparisons with selected peer companies. Cash flow models encapsulate the cash streams forecast to flow to a company, and are widely used in the investment industry. Peer comparisons factor in amongst other factors, differential growth rates, and indicate how expensive one company might appear relative to a chosen comparator. The subjective opinions of the document's author or authors, formed by their knowledge and experience, play a significant role in the valuation. Also included are assumptions on numerous economic variables, particularly interest rates, inflation and exchange rates and varying these assumptions could result in significantly different opinions. The strength of the earnings and cash flow based models is the closer attention to a company on a standalone basis, and tying the valuation to its fundamental value. The weakness of such method is the number of assumptions, which need to be adopted and resulting sensitivity to those assumptions. The peer comparisons methods are less dependent on the analyst's judgment as to the individual parameters, however the problem with this method appears when the peer comparator is over- or undervalued. Moreover, leading multiples (based on the future earnings, book values, operating profit or cash flows) include an analyst's estimate of those values.

This document was not transferred to the company prior to its publication. This document was prepared according to the author's own view, assumptions and knowledge.

It is intended that the analytical report concerning the company will be updated at least twice a year starting from the date of publication of the initiating report, and in the event of key operations and/or changes in the assumptions underlying the report.

Recommendations issued by IPOPEMA Securities S.A. they are valid for a period of 12 months from the date of issue, unless they are updated during this period. IPOPEMA Securities S.A. updates the issued recommendations depending on the market situation and subjective analysts' assessment. In the last 12 months IPOPEMA Securities S.A. has prepared recommendations concerning the company.

List of all recommendations regarding any financial instrument or issuer that have been disseminated within the last 12 months by IPOPEMA Securities S.A. is available on the website at [www.ipopemasecurities.pl](http://www.ipopemasecurities.pl).

This document is an investment research within the meaning of Art. 36 par. 1 of the Commission Delegated Regulation (EU) 2017/565.

The date and the time stated on the front page is the date of the preparation of this document. The price used throughout the recommendation to calculate adequate ratios is the "last" price stated on the front page of this document.

The definitions of terms used in the document include:

NII – Net interest income – interest income minus interest expense.

Net F&C – Net fee and commission income – fee and commission income minus fee and commission expense.

LLP – loan loss provisions – an expense set aside as an allowance for bad loans.

NPL – non-performing loan – loans that are in default or close to be in default.

Cost/Income – operating expenses divided by total banking revenue.

ROE – return on equity – net income (or adjusted net income) divided by the average shareholders' equity.

ROA – return on assets – net income (or adjusted net income) divided by the average assets.

EBIT – earnings before interests and tax.

EBITDA – earnings before interests, tax, depreciation and amortization.

EPS – earnings per share – the net income (or adjusted net income) divided by the number of shares outstanding.

P/E – price to earnings ratio – price divided by earnings per share.

PEG – P/E ratio divided by the annual EPS growth, usually over a certain period of time.

CAGR – compound annual growth rate.

BVPS – book value per share, the book value of the Company's equity divided by the number of shares outstanding.

P/BV – price to book value - price divided by the BVPS.

DPS – dividend per share – dividend of a given year divided by the number of shares outstanding.

DY – dividend yield – dividend of a given year divided by the current price.

DDM – dividend discount model – a fundamental method of valuation based on the assumption that the value of stock equals the sum of all discounted future dividends.

FV – Fair Value, calculated based on valuation methods outlined in the document.

The author of this document has no conflict of interest with the company that is the subject of this document. The point of view expressed in the document reflects the personal opinion of the author of the document on the analyzed company and its financial instruments.

Investors should be aware that flexible part of the author's compensation may depend on general financial performance of IPOPEMA Securities S.A.

IPOPEMA Securities S.A. shall act with due diligence, honestly, fairly, professionally and in accordance with the provisions of the applicable law.

IPOPEMA Securities S.A. does not guarantee achieving the investor's investment objective, the performance of company or prospective prices referred to herein.

When applying ratings for companies following criteria are used with regards to the difference between IPOPEMA's FV and company's price at the date of recommendation:

Rating	Difference between FV and price at recommendation
Buy	Above 10%
Hold	In between (and including) -10% and 10%
Sell	Below -10%

#### IPOPEMA Research - Distribution by rating category (April 1 – June 30, 2020)

	Number	%
Buy	23	55%
Hold	11	26%
Sell	8	19%
Total	42	100%

#### Rating History – Capital Park

Date	Recommendation	Fair Value	Price at recommendation	Author
30/07/2019	BUY	PLN 8.50	PLN 5.44	Marek Szymański
11/10/2019	BUY	PLN 8.99	PLN 6.13	Marek Szymański
25/05/2020	BUY	PLN 6.89 (adj. on DPS of PLN 2.1)	PLN 6.96	Marek Szymański
22/07/2020	BUY	PLN 8.25	PLN 6.70	Marek Szymański